Listen to The Lancet Respiratory Medicine

Markus Maeurer discusses the Tuberculosis 2014 Series, which features papers from The Lancet Respiratory Medicine and The Lancet Infectious Diseases.

Tim Dehnel is joined by Judith Nelson and Elie Azoulay to discuss whether intensive care medics should also be palliative specialists.

Victor Ortega discusses the effect of rare ADRB2 variants of risk on severe asthma exacerbations in patients receiving treatment with LABAs.

Geoff Bellingan discusses the effect of intravenous-beta-1a on lung CD73 expression and on ARDS mortality.

Klaus Rabe discusses a study that looks at ADRB2 polymorphisms and drug efficacy in preventing COPD exacerbations in patients from the POET trial.

Stefano Guerra discusses whether club cell secretory protein concentrations predict all-cause and cancer specific mortality in adults.

Clive Page discusses the effects of a novel drug, RPL554, as a bronchodilator and anti-inflammatory drug.

Professor Ganesh Raghu discusses the diagnosis of chronic hypersensitivity pneumonitis in patients with idiopathic pulmonary fibrosis.

Valerie Page discusses the effect of intravenous haloperidol on duration of delirium and coma in critically ill patients.

Jonathan Peter discusses an Article which compares two tuberculosis screening methods in a primary care setting in South Africa.

Dr. Marcelo Cypel discusses a Review on donor management and lung preservation for lung transplantation.

Andres Esteban discusses an article about the chronology of histological lesions in acute respiratory distress syndrome.

Emma Grainger discusses the launch of the inaugural issue of The Lancet Respiratory Medicine.

Claus Vogelmeier discusses a study comparing two types of inhalers for chronic obstructive pulmonary disease (COPD).

Kerri Johannson from the University of Calgary discusses why recent treatment guidelines on the use of antacid therapy in patients with IPF have caused controversy.

Dr. Ganesh Raghu discusses the highly anticipated results of the WRAP-IPF trial, borne out of debate surrounding the role of GER in the pathogenesis and progression of IPF, and conflicting findings from retrospective studies of antacid therapies on survival and disease progression.

Prof. James Chalmers discusses the characteristics of patients with bronchiectasis across Europe, the differences between countries, and possible differences in clinical outcomes, based on data from the EMBARC registry.

Dr Keith Chappell discusses the bivalent recombinant vaccine for COVID-19 following the study by Dayan and colleagues, with focus on vaccine access, variants and boosters, tolerability and side effects, as well as hopes for future trials.

Professor Eric Lim discusses the outcomes after extended pleurectomy decortication plus chemotherapy versus chemotherapy alone for pleural mesothelioma.

Dr Margaux Mesle discusses estimates of lives directly saved by COVID-19 vaccination programs in the WHO European Region in the period from 2020 to 2023 and public health implications.

Dr Sandeep Sahay and Professor Franck Rahaghi discuss their Personal View on future treatment paradigms in pulmonary arterial hypertension.